Optimal dilution of the VDR antibody should be determined by the researcher.\. Western blot: 0.1-0.5 μg/mL,IHC (Paraffin): 0.5-1 μg/mL
Beschränkungen
Nur für Forschungszwecke einsetzbar
Buffer
0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
Lagerung
-20 °C
Informationen zur Lagerung
After reconstitution, the VDR antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.
vdrbeta antikoerper, vdr0 antikoerper, LOC100136219 antikoerper, NR1I1-B antikoerper, gb:dq017633 antikoerper, vdr-b antikoerper, Ci-VDR-b antikoerper, VDR antikoerper, LOC100221284 antikoerper, vdr-A antikoerper, xVDR antikoerper, Nr1i1 antikoerper, vdr antikoerper, NR1I1 antikoerper, PPP1R163 antikoerper, vitamin D (1,25- dihydroxyvitamin D3) receptor antikoerper, vitamin D receptor antikoerper, vitamin D3 receptor A antikoerper, vitamin D receptor b antikoerper, nuclear receptor VDR-b antikoerper, vitamin D (1,25- dihydroxyvitamin D3) receptor L homeolog antikoerper, vitamin D (1,25-dihydroxyvitamin D3) receptor antikoerper, vitamin D receptor a antikoerper, vdr antikoerper, vdr0 antikoerper, VDR antikoerper, LOC100136219 antikoerper, vdrb antikoerper, vdr-b antikoerper, vdr.L antikoerper, Vdr antikoerper, vdra antikoerper
Substanzklasse
Chemical
Hintergrund
VDR (Vitamin D Receptor), also known as Vitamin D Hormone Receptor, is a member of the nuclear receptor family of transcription factors. Labuda et al. (1991) assigned the VDR gene to 12q12-q14 by in situ hybridization. Using mutation analysis, Jurutka et al. (2000) characterized arg18/arg22, VDR residues immediately N-terminal of the first DNA-binding zinc finger, as vital for contact with the general transcription factor IIB (TFIIB). A natural polymorphic variant of VDR, termed F/M4 (missing a FokI restriction site), which lacks only the first 3 amino acids (including glu2), interacted more efficiently with TFIIB and also possessed elevated transcriptional activity compared with the full-length (f/M1) receptor. Shah et al. (2006) stated that the signaling and oncogenic activity of beta-catenin (CTNNB1) can be repressed by activation of VDR. Conversely, high levels of beta-catenin can potentiate the transcriptional activity of 1,25- dihydroxyvitamin D3.